On Jun. 8, 2020, Innovent Biologics announced a strategic research and development collaboration with Roche covering multiple cell therapies and bispecific antibodies. The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.